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 Abstract 
 
A new method using high performance liquid chromatography coupled with electrospray mass 
spectrometry is described for the quantification of PBMC concentration of tyrosine kinase inhibitors 
imatinib, dasatinib and nilotinib. A simple PBMC isolation and extraction procedure were applied 
on 10-14 mL of blood aliquots. Chromatographic separation of drugs and Internal Standard 
(quinoxaline) was achieved with a gradient (acetonitrile and water + formic acid 0.05%) on a C18 
reverse phase analytical column with 25 min of analytical run, at flow rate of 0.25 mL/min. Mean 
intra- and inter-day precision for all compounds were 8.76 and 12.20%; mean accuracy was -3.86%; 
extraction recovery ranged within 79 and 91%. Calibration curves ranged from 50.0 to 0.25 ng. The 
limit of quantification was set at 0.25 ng for all the analyzed drugs. 
This novel developed methodology allows a specific, sensitive and reliable simultaneous 
intracellular determination of the three tyrosine kinase inhibitors imatinib, dasatinib and nilotinib in 
a single chromatographic run, useful for drugs estimation in PBMC of patients affected by chronic 
myeloid leukemia. 
 
1. Introduction 
Chronic myeloid leukemia (CML) is a myeloproliferative disorder, characterized by the presence of 
the Philadelphia chromosome, consequence of a translocation 9-22, producing a fusion oncogene 
referred to as BCR-ABL, encoding for a BCR-ABL kinase [1]. Thus, the use of BCR-ABL-targeted 
therapy is the standard of care for this disease. Current frontline therapy for CML is imatinib 
(GleevecTM, STI-571), a 2-phenylaminopyrimidine-type inhibitor of the BCR-ABL kinase [2], that 
competitively inhibits the binding of ATP to the ATP binding pocket of BCR-ABL [3-4]. In the 
International Randomized Study of Interferon and STI571 (IRIS; ClinicalTrials.gov number, 
NCT00006343), imatinib has been associated with a superior response rate and improved 
progression-free survival, as compared with the previous standard therapy, interferon alfa plus low-
dose cytarabine [5-7]. Eight-year follow-up of IRIS revealed that responses to imatinib were 
durable and had an acceptable adverse-event profile, with an estimated rate of overall survival of 
85% [8]. Although most patients show excellent responses to imatinib treatment, nearly 20% of 
patients who take the drug do not have a complete cytogenetic response, and others may have 
intolerable side effects or drug resistance over time [8]. Resistance, mainly caused by point 
mutations, leads to a reduced affinity of imatinib for the ATP binding domain of the BCR-ABL 
protein and to a reactivation of the BCR-ABL kinase activity [9-10]. Loss of response and 
transformation to advanced disease occur mainly in the first 3 years of imatinib therapy, inducing a 
rate of overall survival often poor in these patients [8]. To overcome imatinib resistance and 
intolerance, more potent tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have 
been developed for the treatment of CML. Dasatinib (Sprycel
TM
, BMS-354825) is a structurally 
distinct drug which has a more potent activity than imatinib [11-12]. It also inhibits Src kinases, 
proteins that play a critical role in the development, growth, progression, and metastasis of a 
number of human cancers [13]. Dasatinib offers a new treatment option for patients with CML or 
Ph-positive acute lymphoblastic leukemia who are either unable to tolerate or resistant to previous 
therapy, including imatinib. Dasatinib has been found to be more effective in eliciting a cytogenetic 
or hematologic response and better tolerated than high-dose imatinib. However, many factors play a 
role in determining whether dasatinib may provide benefit to patients. Some of these factors are 
known, such as BCR-ABL-sensitive mutations, whereas other mechanisms of CML not related to 
BCR-ABL are unknown or unclear [14]. Another second generation TKI is Nilotinib (TasignaTM, 
AMN107). It is a close analog of imatinib with higher potency and selectivity for BCR-ABL kinase 
inhibition in-vitro and in-vivo than imatinib [15-16]. Nilotinib was first approved in the United 
States and elsewhere in 2007 for patients with CML in the chronic or accelerated phase who had 
resistance to or could not tolerate imatinib [17-18]. In a phase 3 study, randomized, open-label, 
multicenter trial, authors compared the efficacy and safety of nilotinib with that of imatinib. 
Analysis was done for patients with newly diagnosed Philadelphia chromosome–positive CML in 
the chronic phase, with the rate of major molecular response at 12 months as the primary end point. 
Study showed more efficacy for nilotinib [19].  
Due to the large TKIs proposal in CML treatment, imatinib-resistant patients may find the right path 
to reach clinical effectiveness. A good help may be also offered to this purpose by employing of 
therapeutic drug monitoring (TDM), essential tool, today, for the management of CML patients. 
Sub-inhibitory drug concentrations and sequential treatment with multiple TKIs can promote, in 
fact, the selection of BCR-ABL kinase domain mutations in CML patients. Measurement of 
antileukemia drugs plasma concentrations reached by treated patients, then, can be useful to 
monitor CML patients over time, leading the evaluation of patient adherence to daily oral therapy, 
potential drug–drug interactions, treatment efficacy, and severe drug-related adverse events [20-21].  
In recent years, numerous laboratories have reported the use of high-throughput bioanalytical 
procedures for the single and simultaneous quantification of plasma concentrations of antileukemia 
drugs [22-35]. Based on validated high performance liquid chromatography (HPLC) methods, the 
plasma pharmacokinetics (PK) of imatinib has been well investigated, while only few paper on the 
PK of dasatinib and nilotinib are available to date [11-21-36-39]. If data miss about plasmatic PK, 
no literature exist at all related to intracellular quantification of all TKIs, included imatinib. Topic 
that should be deeply investigated, instead, in order to have a better indication about ongoing 
treatment efficacy. Measurement of TKIs plasma concentrations, in fact, is a reliable tool to 
perform TDM; however, only the drugs fraction reaching the intracellular compartment is expected 
to exert action. Then a convenient correlation should be done, also, between clinical outcome and 
intracellular drug levels reached in treated patients. As variability in drug PK and inadequate patient 
compliance, also poor penetration of drugs into body compartments, particularly in leukocytes or 
peripheral blood mononuclear cell (PBMC), may contribute to the occurrence of sub-therapeutic 
drug level, leading loss of treatment efficacy. By the way the mechanisms by which TKIs drugs 
accumulate within cells remain generally unknown and it should be further investigated, because 
very few data are published to date [26-40-42]. Moreover, a number of transmembrane transport 
proteins, such as P-glycoprotein, the gene product of ABCB1 (MDR1), and related ABC (ATP 
binding cassette) B1 (ABCB1), ABCG2, such as solute carrier 22A1 (SLC22A1), solute carrier 
organic anion transporter family members 1B1 (SLCO1B1) and SLCO1B3 transporters are known 
to actively mediate the efflux and uptake of drugs from cells. The genes coding for these transport 
and regulatory proteins are polymorphic in humans, with consequences on the expression and 
function, potentially influencing the intracellular levels of TKIs drugs. In particular was observed in 
CML patients an association of SLCO1B3 polymorphism with intracellular accumulation of 
imatinib in leukocytes [42]. Thus, as intracellular concentrations of TKIs drugs are influenced by 
both their physico-chemical properties and host genetic factors, an assay enabling the monitoring of 
TKIs levels at the site of their pharmacological action, appears to be an essential tool for the 
ongoing investigations aimed at preventing TKIs therapy failure or toxicity. 
Herein, aim of our study was to develop and validate an HPLC method coupled with electrospray 
mass spectrometry (HPLC–MS) detection for the simultaneous quantification of imatinib, dasatinib 
and nilotinib in human PBMC.  
 
2. Experimental 
2.1. Chemicals 
Imatinib (GlivecTM, STI-571) and nilotinib (TasignaTM, AMN-107) were kindly supplied by Novartis 
Pharma AG (Basel, Switzerland); dasatinib (SprycelTM, BMS-354825) was purchased from Sequoia 
Research (Pangbourne, United Kingdom). Acetonitrile HPLC grade and methanol HPLC grade 
were purchased from J.T. Baker (Deventer, Holland). HPLC grade water was produced with Milli-
DI system coupled with a Synergy 185 system by Millipore (Milan, Italy). Quinoxaline (QX) and 
formic acid were obtained from Sigma–Aldrich (Milan, Italy). Lymphoprep was purchased from 
Sentinel Diagnostics (Milan, Italy). Blank cells (PBMCs) were isolated from the blood of healthy 
donors, kindly supplied by the Blood Bank of the Maria Vittoria Hospital (Turin, Italy).  
 
2.2. Stock solutions, standards (STD) and quality controls (QC) 
The stock solutions of imatinib, dasatinib and nilotinib were prepared by dissolving an accurately 
weighed amount of drug in methanol to obtain a final concentration of 1 mg/mL; all stock solutions 
were then stored at -20°C. The stock solutions were stored maximum 3 months.  
The Internal Standars (IS) working solution was prepared with QX [1 g/mL] in methanol and 
HPLC grade water (50:50 v/v) and stored at 4°C until use. The six calibration standards and three 
quality controls (QCs) were prepared adding a determined volume of stock solutions, or diluted 
stock solution, to each blank PBMCs aliquots before storage at –80°C, during no more than three 
months, in a manner similar to that described in other publications [43-44]. 
Calibration ranges, from STD 6 to STD 1, and QC amount for all drugs are listed in Table 1. 
 
 
2.3 PBMC isolation.  
Clinical samples were collected, after obtaining written informed consent according to local Ethics 
Committee indications, from patients treated with TKIs. Blood samples were collected in two 
EDTA tubes (2x7 mL). 
PBMCs were isolated from 10 to 14 mL of blood using lymphoprep density gradient centrifugation 
(700 g, 25 min, 4°C with a Jouan Centrifuge [Model BR4i, Saint-Herblain, France]) at each 
sampling, as described previously [44]. PBMCs were then fast washed twice in 40 mL cold-ice 
phosphate-buffered saline and centrifuged (750 g, 6 min, 4°C).  
The resulting pellet of washed PBMCs was dissolved with 1 mL extraction solution 
(methanol:water, 70:30 vol/vol), switched in two criovials (500 l each) and then stored at –80°C 
until analyses, and for no longer than three months.  
The time taken to process PBMCs from phlebotomy to methanol extraction solution was less than 1 
hour, ensuring that sampling conditions were ice cold to prevent drug loss [45-46]. Blank PBMCs 
isolated from the blood of healthy donors, as previously described, were stored in aliquots of around 
5x10
6
 cells. 
The cell number were afterwards determined by absorbance with a new procedure (paper in 
progress). This method used 10 microliters of stored unknown number PBMC aliquots versus 10 
microliters of known numbers of PBMC reference aliquots. The known number of the reference 
aliquots were obtained by a Bekman Coulter Z2 (Instrumentation Laboratory, Milan, Italy), and 
managed by Z2 AccuComp Software (Version 3.01), without the use of the trypan blue exclusion. 
The cellular volume used to calculate intracellular concentrations of TKIs was 285 femto-Liters, as 
described previously [47]. 
 
2.4. STD, QC and samples preparation 
The stored aliquots of STDs, QCs and patient samples PBMCs were defrosted at room temperature. 
Fifty l of IS working solution were added to each tube and the samples were vortexed for 10 
seconds. STDs, QCs and patient tube samples were sonicated in an ice-water bath three time (Cycle 
0,75; Amplitude 80%), to fully lyse PBMCs, using a sonicator UP-50 H (Dr Hielscher GmbH, 
Teltow, Germany). After a centrifugation at (7.000 g, 10 minutes at 4°C), 10 l of supernatant were 
used for the cell count, and the remainder supernatant were collected into glass tubes. The 
remaining pellets were then washed by vortex for 10 seconds with 200 l of acetonitrile:metanol 
solution (50:50, vol/vol), centrifuged (7.000 g, 10 minutes at 4°C) and each supernatant was 
collected in the indicated glass tubes to be treated by vortex-vacuum evaporation to dryness at 
60°C. 
Each extract was reconstituted with 60 l of HPLC-grade water and acetonitrile solution (60:40, 
vol/vol) and 20 l were injected into the column. For validation purposes, all samples were 
extracted and analyzed in duplicate. All procedure steps were carried out at room temperature, 
excluding that of sonication. 
 
  
2.5. Chromatographic and MS conditions 
The HPLC-MS instrument used was a Waters system (Milan, Italy), with binary pump model 1525, 
AF degaser, 717-plus autosampler, and Micromass ZQ mass detector. LC-MS Empower Pro 
software (version year 2002, Waters; Milan, Italy) was used.  
The chromatographic separation was performed at 35°C using a column oven, on Atlantis T3 C-18 
3 column (150x2.1 mm I.D.) (Waters; Milan, Italy), protected by a Security Guard with C18 
(4.0x3.0mm I.D.) pre-column (Phenomenex; CA, USA). The chromatographic run was performed 
with a gradient (Table 2), and the mobile phase was composed by HPLC grade water containing 
0.05% formic acid, for mobile phase A, and HPLC grade acetonitrile containing 0.05% formic acid, 
for mobile phase B. 
Detector settings were ESI, positive polarity ionization; capillary voltage 3.5kV; source temperature 
110°C; desolvation temperature 350°C; nitrogen desolvation flow 800 l/h; nitrogen cone flow 100  
l/h. Ions detected, in single ion recording (SIR) mode, were m/z 493.8 with a cone voltage of 45V 
for imatinib, m/z 487.5 with a cone voltage of 35V for dasatinib, m/z 529.5 with a cone voltage of 
35V for nilotinib and m/z 313.0 with a cone voltage of 50V for QX (IS).  
 
 
2.6. Specificity and selectivity 
Interference from endogenous compounds was investigated by analysis of six different blank 
PBMC samples. Moreover interference from some potentially co-administered drugs were 
evaluated for: zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, 
ethambutol, isoniazid, ribavirin, voriconazole, posaconazole and itraconazole (some of many drugs 
routinely analyzed in our laboratory). An “interfering drug” has been considered as a molecule 
which exhibits a retention time close to 0.3 min from the analytes, and with the potential capability 
to cause ion suppression. 
 
 
2.7. Matrix effect 
“Matrix effect” was investigated using six different blank PBMC samples and comparing peak 
areas obtained from standard solutions of a solution of water and acetonitrile (60:40), containing all 
our analytes at three different concentrations, and peak areas obtained from blanks post-extraction 
solution with the same amount of analytes, as described by Taylor [48]. Possible “matrix effect” 
was calculated, as deviation %, comparing the peak area obtained from the PBMC extract with the 
peak area obtained from the standard solution. 
 
2.8. Accuracy, precision, calibration and limit of quantification 
Intra-day and inter-day accuracy and precision were determined by assaying ten spiked PBMC 
samples at three different concentrations (QCs) for each drug. Accuracy was calculated as the 
percent deviation from the nominal concentration. Inter-day and intra-day precision were expressed 
as the standard deviation at each QC concentration. Each calibration curve was obtained using six 
calibration points in duplicate, and the ranges are listed in Table 1. Calibration curves were created 
by plotting the peak area ratios of each drugs relative to the IS against the various drugs 
concentrations in the spiked PBMC standards. A quadratic regression was used for all curves in 
order to obtain the best fit for all calibration points. The limit of detection (LOD) in PBMC was 
defined as the concentration that yields a signal-to-noise ratio of 3/1. The lowest concentration 
levels that could determined with a percent deviation from the nominal concentration and relative 
standard deviation < 20%, was considered the lowest limit of quantification (LOQ), as requested by 
international guidelines [49]. 
 
2.9. Recovery 
Recovery from PBMC, using the extraction procedures, was assessed by comparing the peak area 
obtained from multiple analyses (n=3) of spiked samples (QCs) with the peak area from standard 
solution of all analytes in a solution of water and acetonitrile (60:40) at the same concentrations, as 
described by international guidelines [49]. 
 
2.10. Stability 
The stability of antileukemia drugs at different conditions has been previously assayed in many 
articles [3-25-32-34-50]. For this reason stability assays were not performed. 
 
2.11 Patients PBMC samples 
Patients receiving standard dosing of imatinib, dasatinib or nilotinib, underwent blood sampling 
after obtaining their informed consent for the measurement of PBMC drugs concentrations. Blood 
samples were collected in EDTA tube (2x7 mL) and processed as described above (see section 2.3). 
 
3. Results 
Time of analytical run was chosen as 25 min, according to the retention times of substances, their 
good separation and with the use of a wash column step and its re-equilibration, that allows to 
reduce potential ghost-peak interferences highlighted without the washing step. Our analyte 
retention times were 9.6±0.2 minutes for imatinib, 10.6±0.2 for dasatinib, 12.0±0.2 for nilotinib, 
14.8±0.2 for QX. Representative chromatograms of a blank PBMC extracted and STD1 of imatinib, 
dasatinib and nilotinib are shown in Figure 1A, 1B and 1C, respectively. Representative 
chromatogram of a imatinib, dasatinib and nilotinib STD6 PBMC extracted and QX is shown in 
Figure 2. Mean regression coefficient (r
2
) of all calibration curves was higher than 0.99 for all 
analytes.  
 
3.1. Specificity and selectivity 
The assay did not show any significant interference with other potentially concomitant drugs (see 
section 2.6). The tested six blank PBMC samples did not show any interference in the retention 
times analytes windows for each specified ion detected (Figure 1A, 1B and 1C). 
 
3.2. Accuracy, precision, limit of quantification 
Results of the validation of the method are listed in Table 3 for all analytes. All observed data 
(intra-day and inter-day precision [R.S.D.%]) were all below 15.0%, as request for FDA guidelines 
[49]. LOQ and LOD are listed in Table 1. 
 
3.3. Recovery 
Multiple aliquots (n=3) at each of the three QCs amounts were assayed and mean recovery of drugs 
were 79% for imatinib, 82% for nilotinib and 91% for dasatinib (mean CV, for all drugs, 6.8%). 
Mean IS recovery was 89% (mean CV 2.0%). 
  
3.4. Matrix effect 
The deviation % of the peak area at the three amounts for all analytes is comparable, ranging from –
13.5% to -1.4% (mean -6.4%), showing the absence of the “matrix effect”. 
 
3.5. Analysis of plasma samples from treated patients 
Method developed was applied for assaying of 52 PBMC samples, corresponding to different points 
of time–concentration curve, obtained from 40 patients treated with TKI drugs (28 with imatinib, 4 
with dasatinib, 8 with nilotinib). Values obtained resulted in the expected range of concentrations, 
previously defined in our laboratory (unpublished data) and close to published results by different 
procedure and kind of analyzed cell [26-40-42]. The mean ratios (PBMC/plasma) of Ctrough 
concentrations were 7.8, 35.3 and 5.7 for imatinib, dasatinib and nilotinib, respectively. 
 
4. Discussion and Conclusion 
Targeted therapies using imatinib, dasatinib and nilotinib, based on the inhibition of protein tyrosine 
kinases, represent currently the therapeutic strategies for treatment of CML. TDM, recently, has 
become an essential tool for the management of CML patients, particularly for patients taking 
imatinib [21-39], which efficacy threshold in terms of plasma concentrations is clearly defined. In 
order to manage primary or acquired resistance to imatinib, clinical studies using dasatinib or 
nilotinib as second line therapy or combination of therapies with different TKIs, in sequential or 
simultaneous administration, are currently under evaluation [21-39]. Sub-inhibitory intracellular 
drug concentrations, probably, and sequential treatment with multiple tyrosine kinase inhibitors 
promote the selection of BCR-ABL kinase domain mutations in CML patients [51-52]. Poor 
penetration of drugs into leukocytes or PBMC, inadequate treatment adherence, and variability in 
drug PK may also contribute to the occurrence of sub-therapeutic drug level. In fact, only the 
fraction reaching the intracellular compartment is reasonably expected to exert a therapeutic action. 
Very few data are published to date [26-40-42], probably due to the difficult to develop, validate 
and use, a reliable method to quantify intracellular drug concentration. In this context, aim of our 
study, an HPLC–MS method setting for the simultaneous quantification of TKIs in human PBMC, 
has encountered current need, because no methods for this simultaneous intracellular determination 
of these drugs, are available up to now.  
The method we’ve developed and validated, based on a very close PBMC isolation and drug 
extraction procedure published by our group for antiretroviral drugs [44]. This method can be used 
everywhere, because require instruments available in all laboratories. These procedures were then 
coupled to HPLC instrument with single mass detector. 
For this purpose we have chosen as our internal standard quinoxaline, as it is easy to purchase, 
inexpensive (compared with deuterated drug isotopes) and reliable in its chemical behavior. This 
xenobiotic was fully used as IS in our other validated method [25-44-53-60], with UV and mass 
detectors. Moreover it is not a potential coadministred drug as was the case in other studies [41-42]. 
The method developed is suitable to be used in clinical studies due to its high extraction efficiency, 
its high sensitivity, its good reproducibility and due to the simultaneous quantification of the three 
drugs using a small volumes of blood (10-14 mL). 
In fact, since no therapeutic window has been clearly defined for the imatinib, dasatinib and 
nilotinib in PBMC, as in plasma (excluding imatinib [36-38-39]), it could be interesting try to 
quantify intracellular concentrations of the three drugs and assess at first potential correlation with 
plasma concentrations, then a concentration-response relationship. At present no reports showed 
data related to intracellular levels. Moreover, measurement of antileukemia intracellular 
concentrations, even if more elaborated than TKIs plasma determination, can be useful, as plasma 
concentration, to evaluate patient adherence to daily oral therapy, treatment efficacy, severe drug-
related adverse events, and potential drug–drug interactions, especially in patients who must take 
drugs interfering with cytochrome P450 [20].  
Moreover, TKIs are substrate of transmembrane transport proteins encoded by ABCB1, SLCO1B1 
and SLCO1B3 gene [42]. The genes coding for these transport are polymorphic with consequences 
on the expression and function, potentially influencing the intracellular levels of TKI drugs. 
The LOQ (0.25 ng) and calibration curves included a wide range of imatinib, dasatinib and nilotinib 
concentrations/amounts, optimized according to expected and founded ranges of drug 
concentrations in PBMC patients. Choice of limits of these ranges was based on the values available 
in the clinical reports, too [26-40-42].  
Data of the developed assay makes our method suitable, then, to perform imatinib, dasatinib and 
nilotinib quantification in PBMC CML patients. Reliability of our method has been demonstrated 
for all drug concentrations; relative error at QCs concentrations, intra-day and inter-day precision 
(Table 3) indicate the good performances of our method. Absence of interference peaks at the 
analyte retention times, without a “matrix effect”, coupled with an experienced collection procedure 
and treatment of PBMC [44] allowed accurate measurement of drugs intracellular levels.  
 
5 Conclusion 
We report a new method using HPLC-MS for the simultaneous intracellular determination of 
imatinib, dasatinib and nilotinib in a single chromatographic run. The selectivity of the assay 
described could be exploited optimally when monitoring all the three substances in PBMC and/or 
tissues during animal and clinical PK studies of single or concomitant administration. The described 
HPLC-MS method allows the rapid, simple, sensitive, and selective simultaneous intracellular 
quantification of the three major antileukemia drugs. This method could be currently used for the 
clinical study (or monitoring) of PBMC TKIs concentrations in patients treated with imatinib, 
dasatinib and/or nilotinib.  
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 Table 1. Detected mass (Dalton), cone voltage used (Volts) and retention time (RT, in minutes) used to quantify Internal Standard and each drug, 
and absolute amounts from STD6 to STD1 (LOQ), QCs (QC high, QC medium and QC low) and LOD.  
Drugs Data Amounts (ng) 
Drugs 
RT 
(minutes) 
Mass 
(dalton) 
Cone 
Voltage 
(volts) 
STD 
6 
STD 
5 
STD 
4 
STD 
3 
STD 2 
LOQ / 
STD 1 
QC 
High 
QC 
Medium 
QC Low LOD 
Imatinib 9.6 493.80 45 50 10 5 2 0.5 0.25 8 4 1 0.06 
Dasatinib 10.6 487.50 35 50 10 5 2 0.5 0.25 8 4 1 0.06 
Nilotinib 12.0 529.50 35 50 10 5 2 0.5 0.25 8 4 1 0.06 
IS 14.8 313.30 50 - - - - - - - - - - 
 
 
Table 2. Chromatographic condition (gradient): Mobile Phase A (HPLC grade water + 0.05% 
formic acid) and Mobile Phase B (HPLC grade acetonitrile + 0.05% formic acid). The flow was 
0.25 ml/min. 
 
TIME (min.) 
% Mobile Phase 
A 
% Mobile Phase 
B 
0.0 74 26 
0.1 73 27 
2.0 55 45 
4.0 50 50 
9.0 40 60 
9.5 30 70 
9.6 5 95 
14.0 5 95 
14.1 95 5 
15.1 95 5 
25.0 75 25 
 
 
 
 25 
Table 3. Accuracy (CV%), Intraday and Interday Precision, as relative standard deviation (RSD%), assayed for all drugs (n=10). 
 
Drugs QC high   QC medium   QC low 
 
Accuracy % 
Precision R.S.D. % 
 
Accuracy % 
Precision R.S.D. % 
 
Accuracy % 
Precision R.S.D. % 
  Intra-day Inter-day   Intra-day Inter-day   Intra-day Inter-day 
IMATINIB -5.72% 7.57% 11.04%   -4.56% 8.54% 13.01%   -6.63% 10.69% 14.12% 
DASATINIB 2.68% 7.98% 10.73%   -4.22% 8.98% 11.28%   -3.60% 9.53% 12.28% 
NILOTINIB 2.05% 7.60% 10.61%   -5.77% 7.99% 12.56%   -8.96% 9.94% 14.18% 
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Figure 1. Overlapping of STD1 and blank PBMC extracted ions detection (A, Imatinib; B, Dasatinib; C 
Nilotinib). 
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Figure 2. STD6 extracted chromatogram. 
 
 
